ALNY

Alnylam Pharmaceuticals Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$43.19B
P/E Ratio
80.67
EPS
$4.01
Beta
0.27
52W High
$495.55
52W Low
$273.11
50-Day MA
$296.39
200-Day MA
$364.89
Dividend Yield
Profit Margin
12.60%
Forward P/E
34.13
PEG Ratio
0.54

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$4.29B
Gross Profit (TTM)$3.46B
EBITDA$806.94M
Operating Margin23.00%
Return on Equity90.40%
Return on Assets10.10%
Revenue/Share (TTM)$32.52
Book Value$8.06
Price-to-Book38.83
Price-to-Sales (TTM)10.08
EV/Revenue9.34
EV/EBITDA46.24
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)96.40%
Shares Outstanding$133.51M
Float$132.94M
% Insiders0.18%
% Institutions102.00%

Historical Volatility

HV 10-Day
22.97%
HV 20-Day
28.25%
HV 30-Day
32.52%
HV 60-Day
32.95%
HV Rank
30.2%

Volatility is currently contracting

Analyst Ratings

Consensus ($437.50 target)
7
Strong Buy
14
Buy
8
Hold

Latest News

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry's most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyon.

Business Wire6/25/2026Neutral
The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Forbes6/17/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026